Corresponding Author: Silje Watterdal Syversen, MD, PhD, Division of Rheumatology and Research, Diakonhjemmet Hospital, PO Box 23 Vinderen, N-0319 Oslo, Norway (s.w.syversen@gmail.com).
Accepted for Publication: November 9, 2021.
Author Contributions: Drs Syversen and Sexton had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Syversen, Jørgensen, and Goll contributed equally. Drs Jahnsen, Bolstad, and Haavardsholm contributed equally.
Concept and design: Syversen, Jørgensen, Goll, Sandanger, Sexton, Olsen, Gehin, Mørk, Kvien, Jahnsen, Bolstad, Haavardsholm.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Syversen, Jørgensen, Goll, Brun, Bjørlykke, Sexton, Gehin, Mørk, Kvien, Jahnsen, Bolstad.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Syversen, Brun, Bjørlykke, Sexton, Olsen, Haavardsholm.
Obtained funding: Syversen, Kvien, Bolstad, Haavardsholm.
Administrative, technical, or material support: Syversen, Jørgensen, Goll, Brun, Sandanger, Bjørlykke, Sexton, Gehin, Warren, Klaasen, Noraberg, Bruun, Dotterud, Ljoså, Haugen, Njålla, Zettel, Ystrøm, Bragnes, Skorpe, Thune, Seeberg, Michelsen, Blomgren, Strand, Mielnik, Torp, Mørk, Kvien, Jahnsen, Bolstad, Haavardsholm.
Supervision: Syversen, Jørgensen, Goll, Brun, Sandanger, Bjørlykke, Sexton, Gehin, Noraberg, Bruun, Dotterud, Ljoså, Haugen, Njålla, Zettel, Ystrøm, Bragnes, Skorpe, Thune, Seeberg, Michelsen, Blomgren, Strand, Mielnik, Torp, Mørk, Kvien, Jahnsen, Bolstad, Haavardsholm.
Conflict of Interest Disclosures: Dr Syversen reported receipt of personal fees from Thermo Fisher. Dr Jørgensen reported receipt of personal fees from Bristol Myers Squibb, Roche, Celltrion, and Norgine. Dr Goll reported receipt of personal fees from AbbVie, Pfizer, Sandoz, Celltrion, Lilly, UCB, and Boehringer Ingelheim. Dr Dotterud reported receipt of personal fees from LEO Pharma. Dr Michelsen reported receipt of personal fees from Novartis and grants from Novartis paid to her employer. Dr Mørk reported receipt of personal fees from Novartis Norge, LEO Pharma, ACO Hud Norge, Cellgene, AbbVie, and Galderma Nordic. Dr Kvien reported receipt of grants from AbbVie, Amgen, Bristol Myers Squibb, Novartis, Pfizer, and UCB and personal fees from Amgen, Celltrion, Egis, Evapharma, Ewopharma, Gilead, Hikma, Mylan, Oktal, Pfizer, Sandoz, Sanofi, and UCB. Dr Bolstad reported receipt of personal fees from Roche, Janssen, and Novartis. Dr Haavardsholm reported receipt of personal fees from Pfizer, AbbVie, Celgene, Novartis, Janssen, Gilead, Lilly, and UCB. No other disclosures were reported.
Funding/Support: This study was funded by grants from the Norwegian Regional Health Authorities (interregional KLINBEFORSK grants) and the South-Eastern Norway Regional Health Authorities. The sponsor of the study was Diakonhjemmet Hospital.
Role of the Funder/Sponsor: Neither the funder of the study (the Regional Health Authorities) nor the sponsor (Diakonhjemmet Hospital) had any role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Neither the funder nor the sponsor had any right to veto publication or to control the decision regarding to which journal the manuscript was submitted. All drafts of the manuscript were prepared by the authors. All authors approved the final submitted version.
Additional Contributions: We acknowledge the patient representatives, Jon Hagfors (Norwegian Rheumatism Association), Bjørn Gulbrandsen (Norwegian IBD Patient Organization), and Hilde Mellum (Psoriasis and Eczema Association of Norway), for their contributions during planning and conduct of the study. We acknowledge the members of the scientific advisory board, Josef Smolen, MD, PhD (University of Vienna), Alejandro C. Balsa, MD, PhD (University Hospital La Paz, Madrid), Geert D’Haens, MD, PhD (Amsterdam Academic Medical Center), Jørn Brynskov, MD, PhD (University of Copenhagen Herlev Hospital), and Diamant Thaci, MD, PhD (University of Lubeck). No compensation was received for their contributions to the protocol. We acknowledge Cecilie Moe, Bjørn Solvang, Nina Flatner, Trond Smedsrud, and Marius Eid, Department of Research Support for Clinical Trials at Oslo University Hospital, and Anja Bye, Clinical Research Unit Central Norway, for research support and data management (received compensation for their work).
Data Sharing Statement: See Supplement 3.
1.Roda
G , Jharap
B , Neeraj
N , Colombel
JF . Loss of response to anti-TNFs: definition, epidemiology, and management.
Clin Transl Gastroenterol. 2016;7(1):e135. doi:
10.1038/ctg.2015.63PubMedGoogle Scholar 3.Movahedi
M , Hepworth
E , Mirza
R , Cesta
A , Larche
M , Bombardier
C . Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: results from a real-world rheumatoid arthritis cohort.
Semin Arthritis Rheum. 2020;50(5):915-922. doi:
10.1016/j.semarthrit.2020.06.020PubMedGoogle ScholarCrossref 4.Flurey
CA , Morris
M , Richards
P , Hughes
R , Hewlett
S . It’s like a juggling act: rheumatoid arthritis patient perspectives on daily life and flare while on current treatment regimes.
Rheumatology (Oxford). 2014;53(4):696-703. doi:
10.1093/rheumatology/ket416PubMedGoogle ScholarCrossref 5.Markusse
IM , Dirven
L , Gerards
AH ,
et al. Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BEST study.
Arthritis Res Ther. 2015;17(1):232. doi:
10.1186/s13075-015-0730-2PubMedGoogle ScholarCrossref 9.St Clair
EW , Wagner
CL , Fasanmade
AA ,
et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum. 2002;46(6):1451-1459. doi:
10.1002/art.10302PubMedGoogle ScholarCrossref 10.Maneiro
JR , Salgado
E , Gomez-Reino
JJ . Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis.
JAMA Intern Med. 2013;173(15):1416-1428. doi:
10.1001/jamainternmed.2013.7430PubMedGoogle ScholarCrossref 14.Syversen
SW , Goll
GL , Jørgensen
KK ,
et al. Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study).
Trials. 2020;21(1):13. doi:
10.1186/s13063-019-3734-4PubMedGoogle ScholarCrossref 15.Syversen
SW , Goll
GL , Jørgensen
KK ,
et al. Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial.
JAMA. 2021;325(17):1744-1754. doi:
10.1001/jama.2021.4172PubMedGoogle ScholarCrossref 17.Jørgensen
KK , Olsen
IC , Goll
GL ,
et al; NOR-SWITCH Study Group. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Lancet. 2017;389(10086):2304-2316. doi:
10.1016/S0140-6736(17)30068-5PubMedGoogle ScholarCrossref 18.Prevoo
ML , van ’t Hof
MA , Kuper
HH , van Leeuwen
MA , van de Putte
LB , van Riel
PL . Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.
Arthritis Rheum. 1995;38(1):44-48. doi:
10.1002/art.1780380107PubMedGoogle ScholarCrossref 19.England
BR , Tiong
BK , Bergman
MJ ,
et al. 2019 Update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures.
Arthritis Care Res (Hoboken). 2019;71(12):1540-1555. doi:
10.1002/acr.24042PubMedGoogle ScholarCrossref 20.Lukas
C , Landewé
R , Sieper
J ,
et al; Assessment of Spondyloarthritis International Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.
Ann Rheum Dis. 2009;68(1):18-24. doi:
10.1136/ard.2008.094870PubMedGoogle ScholarCrossref 21.Machado
P , Landewé
R , Lie
E ,
et al; Assessment of Spondyloarthritis International Society. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.
Ann Rheum Dis. 2011;70(1):47-53. doi:
10.1136/ard.2010.138594PubMedGoogle ScholarCrossref 22.Lewis
JD , Chuai
S , Nessel
L , Lichtenstein
GR , Aberra
FN , Ellenberg
JH . Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis.
Inflamm Bowel Dis. 2008;14(12):1660-1666. doi:
10.1002/ibd.20520PubMedGoogle ScholarCrossref 24.Vermeire
S , Schreiber
S , Sandborn
WJ , Dubois
C , Rutgeerts
P . Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity.
Clin Gastroenterol Hepatol. 2010;8(4):357-363. doi:
10.1016/j.cgh.2010.01.001PubMedGoogle ScholarCrossref 26.Turner
D , Ricciuto
A , Lewis
A ,
et al; International Organization for the Study of IBD. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD.
Gastroenterology. 2021;160(5):1570-1583. doi:
10.1053/j.gastro.2020.12.031PubMedGoogle ScholarCrossref 27.Papamichael
K , Van Stappen
T , Vande Casteele
N ,
et al. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis.
Clin Gastroenterol Hepatol. 2016;14(4):543-549. doi:
10.1016/j.cgh.2015.11.014PubMedGoogle ScholarCrossref 30.Fernandes
SR , Bernardo
S , Simões
C ,
et al. Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease.
Inflamm Bowel Dis. 2020;26(2):263-270. doi:
10.1093/ibd/izz131PubMedGoogle ScholarCrossref 31.Papamichael
K , Chachu
KA , Vajravelu
RK ,
et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab.
Clin Gastroenterol Hepatol. 2017;15(10):1580-1588. doi:
10.1016/j.cgh.2017.03.031PubMedGoogle ScholarCrossref 32.D’Haens
G , Vermeire
S , Lambrecht
G ,
et al; GETAID. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn’s disease.
Gastroenterology. 2018;154(5):1343-1351. doi:
10.1053/j.gastro.2018.01.004PubMedGoogle ScholarCrossref 34.Feuerstein
JD , Nguyen
GC , Kupfer
SS , Falck-Ytter
Y , Singh
S ; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease.
Gastroenterology. 2017;153(3):827-834. doi:
10.1053/j.gastro.2017.07.032PubMedGoogle ScholarCrossref 36.Berth-Jones
J , Grotzinger
K , Rainville
C ,
et al. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician’s Global Assessment and Lattice System Physician’s Global Assessment.
Br J Dermatol. 2006;155(4):707-713. doi:
10.1111/j.1365-2133.2006.07389.xPubMedGoogle ScholarCrossref 38.Lamb
CA , Kennedy
NA , Raine
T ,
et al; IBD Guidelines eDelphi Consensus Group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.
Gut. 2019;68(suppl 3):s1-s106. doi:
10.1136/gutjnl-2019-318484PubMedGoogle ScholarCrossref 39.Mitrev
N , Vande Casteele
N , Seow
CH ,
et al; IBD Sydney Organisation and Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
Aliment Pharmacol Ther. 2017;46(11-12):1037-1053. doi:
10.1111/apt.14368PubMedGoogle ScholarCrossref 40.Takeuchi
T , Miyasaka
N , Inoue
K , Abe
T , Koike
T ; RISING Study. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING Study.
Mod Rheumatol. 2009;19(5):478-487. doi:
10.3109/s10165-009-0195-8PubMedGoogle ScholarCrossref